Movement Alert｜Argenx SE Rises 3.25% in Regular Trading, Bullish Sentiment Builds Ahead of Q2 Earnings Release

Market Focus

Jul 22

On July 22, Argenx SE rose 3.25% in regular trading, trading at $873.67/share, with turnover of $186 million. The move comes one day before the company is scheduled to release its Q2 earnings report on July 23 pre-market.

Market consensus expects Q2 revenue of $1.443 billion, representing 53.14% year-over-year growth, with adjusted EPS forecast at $6.15, up 81.68% year-over-year. Multiple institutions have issued buy ratings, with BNP Paribas initiating coverage at Outperform with a $1,219 price target. The bullish sentiment is underpinned by strong fundamentals: core product Vyvgart recently secured FDA approval expanding its label to all serotypes of generalized myasthenia gravis, which eliminates a key rate-limiting step in prescribing. Additionally, Vyvgart's CIDP patient share is expected to rise from 18% to 23%, supporting continued commercial momentum heading into the earnings print.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1145174951"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1145174951\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1145174951?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-22 03:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1145174951","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Argenx SE Rises 3.25% in Regular Trading, Bullish Sentiment Builds Ahead of Q2 Earnings Release","media":"Market Focus","content":"<p><p>On July 22, Argenx SE rose 3.25% in regular trading, trading at $873.67/share, with turnover of $186 million. The move comes one day before the company is scheduled to release its Q2 earnings report on July 23 pre-market.</p><p>Market consensus expects Q2 revenue of $1.443 billion, representing 53.14% year-over-year growth, with adjusted EPS forecast at $6.15, up 81.68% year-over-year. Multiple institutions have issued buy ratings, with BNP Paribas initiating coverage at Outperform with a $1,219 price target. The bullish sentiment is underpinned by strong fundamentals: core product Vyvgart recently secured FDA approval expanding its label to all serotypes of generalized myasthenia gravis, which eliminates a key rate-limiting step in prescribing. Additionally, Vyvgart's CIDP patient share is expected to rise from 18% to 23%, supporting continued commercial momentum heading into the earnings print.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Argenx SE Rises 3.25% in Regular Trading, Bullish Sentiment Builds Ahead of Q2 Earnings Release</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Argenx SE Rises 3.25% in Regular Trading, Bullish Sentiment Builds Ahead of Q2 Earnings Release\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-22 03:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 22, Argenx SE rose 3.25% in regular trading, trading at $873.67/share, with turnover of $186 million. The move comes one day before the company is scheduled to release its Q2 earnings report on July 23 pre-market.</p><p>Market consensus expects Q2 revenue of $1.443 billion, representing 53.14% year-over-year growth, with adjusted EPS forecast at $6.15, up 81.68% year-over-year. Multiple institutions have issued buy ratings, with BNP Paribas initiating coverage at Outperform with a $1,219 price target. The bullish sentiment is underpinned by strong fundamentals: core product Vyvgart recently secured FDA approval expanding its label to all serotypes of generalized myasthenia gravis, which eliminates a key rate-limiting step in prescribing. Additionally, Vyvgart's CIDP patient share is expected to rise from 18% to 23%, supporting continued commercial momentum heading into the earnings print.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARGX","symbol_name":"Argenx SE","start_time":0,"source_url":"","article_id":"1145174951","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1145174951","pubTimestamp":1784662914,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 22, Argenx SE rose 3.25% in regular trading, trading at $873.67/share, with turnover of $186 million. The move comes one day before the company is scheduled to release its Q2 earnings report...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ARGX":"Argenx SE"},"translate_title":"走势警报|Argenx SE 在常规交易中上涨 3.25%，第二季度财报发布前看涨情绪增强","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARGX":1},"content_text":"On July 22, Argenx SE rose 3.25% in regular trading, trading at $873.67/share, with turnover of $186 million. The move comes one day before the company is scheduled to release its Q2 earnings report on July 23 pre-market.Market consensus expects Q2 revenue of $1.443 billion, representing 53.14% year-over-year growth, with adjusted EPS forecast at $6.15, up 81.68% year-over-year. Multiple institutions have issued buy ratings, with BNP Paribas initiating coverage at Outperform with a $1,219 price target. The bullish sentiment is underpinned by strong fundamentals: core product Vyvgart recently secured FDA approval expanding its label to all serotypes of generalized myasthenia gravis, which eliminates a key rate-limiting step in prescribing. Additionally, Vyvgart's CIDP patient share is expected to rise from 18% to 23%, supporting continued commercial momentum heading into the earnings print.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}